Kite, a Gilead Sciences unit, announced Tuesday that it will acquire Tmunity Therapeutics and expand its pipeline with the biotech’s next-generation CAR T therapies and technologies. Kite didn’t ...
Kite, a Gilead unit, announced Tuesday afternoon that it has hired Cindy Perettie as EVP. In the position, Perettie will oversee the CAR-T unit’s cell therapy business, effective May 30. Most recently ...
Gilead's Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as $2.3B
Gilead Sciences' Kite Pharma unit made its name developing autologous CAR-T treatments made from a patient’s own cells. Now, the subsidiary is making another big play in off-the-shelf treatments that ...
During part of Cindy Perettie’s long run at Roche, the Swiss company put her in command of one of the industry's largest oncology portfolios. A few years later, Perettie will soon find herself running ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback